Roche Diabetes Care expands exclusive distribution agreement with Senseonics for the implantable Eversense® CGM system
- Roche will distribute the Eversense® system across Europe, Middle East and Africa, excluding Scandinavia and Israel.
- Eversense is the first implantable continuous glucose monitoring (CGM) system to measure glucose values for up to 90 days without the need to change the sensor every week.
BASEL, Switzerland, Dec. 2, 2016 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has expanded its exclusive distribution agreement with Senseonics Holdings, Inc. Under the terms of the agreement, Roche will have exclusive rights to promote, market and sell the implantable Eversense CGM system across Europe, Middle East and Africa, excluding Scandinavia and Israel, while Senseonics will retain responsibility for product development, regulatory approval, quality management, and manufacturing. The system will be made available to people with diabetes via clinics and medical practices that have been trained on the system. In May of this year, Roche had already signed an exclusive distribution agreement with Senseonics for its three pilot markets Germany, Italy and the Netherlands.
Photo - http://photos.prnewswire.com/prnh/20161201/444933
"We are excited to build on the good partnership we have formed with Senseonics and provide broad access to innovation to people with diabetes", states Marcel Gmuender, Global Head of Roche Diabetes Care. "The cooperation reinforces our commitment to bring innovation, meet different patient needs and provide true relief."
About Senseonics
Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Senseonics' first generation continuous glucose monitoring (CGM) system, Eversense®, includes a small sensor, smart transmitter and mobile application. Based on fluorescence sensing technology, the sensor is designed to be inserted subcutaneously and communicate with the smart transmitter to wirelessly transmit glucose levels to a mobile device. After insertion, the sensor is designed to continually and accurately measure glucose levels.
For more information on Senseonics, please visit www.senseonics.com.
About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives.
Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices.
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
About Roche Diabetes Care
Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. For more than 40 years, the Accu-Chek brand has been dedicated to enabling people with diabetes to live life as normally and actively as possible as well as to empowering healthcare professionals to manage their patients' condition in an optimal way. Today, the Accu-Chek portfolio offers people with diabetes and healthcare professionals innovative products and impactful solutions for convenient, efficient and effective diabetes management, spanning from blood glucose monitoring through information management to insulin delivery. The Accu-Chek brand encompasses blood glucose meters, insulin delivery systems, lancing devices, data management systems and education programs – contributing to an improved medical outcome.
For more information please visit www.accu-chek.com
All trademarks used or mentioned in this release are protected by law.
Roche Diabetes Care Global Communications Soo-Jin Pak Phone: +41 61 68 78 376 |
Upcoming Life Sciences Events
- April 2024
- Singapore: Asia Bio Partnering Forum
- London: LSX World Congress
- May 2024
- Seoul: BIO KOREA 2024